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Abstract Murine zymosan-induced peritonitis is a widely
used model for studying the molecular and cellular events
responsible for the initiation, persistence and/or resolution of
inflammation. Among these events, it is becoming increasing-
ly evident that changes in glycosylation of proteins, especially
in the plasma and at the site of inflammation, play an impor-
tant role in the inflammatory response. Using matrix-assisted
laser desorption/ionization time-of-flight mass spectrometry
(MALDI-TOF-MS)-based glycosylation profiling, we inves-
tigated the qualitative and quantitative effect of zymosan-
induced peritonitis on N-glycosylation in mouse plasma and
peritoneal fluid. Our results show that both N-glycomes ex-
hibit highly similar glycosylation patterns, consisting mainly
of diantennary and triantennary complex type N-glycans with
high levels (>95 %) of galactosylation and sialylation (mostly
NeuGc) and a medium degree of core fucosylation (30 %).
Moreover, MS/MS structural analysis, assisted by linkage-
specific derivatization of sialic acids, revealed the presence
of O-acetylated sialic acids as well as disialylated antennae
(Bbranching sialylation^) characterized by the presence of
α2-6-linked NeuGc on the GlcNAc of the NeuGcα2-3-
Galβ1-3-GlcNAc terminal motif. A significant decrease of
(core) fucosylation together with an increase of both α2-3-
linked NeuGc and Bbranching sialylation^ were observed in
N-glycomes of mice challenged with zymosan, but not in con-
trol mice injected with PBS. Importantly, substantial changes
in glycosylation were already observed 12 h after induction of
peritonitis, thereby demonstrating an unexpected velocity of
the biological mechanisms involved.
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Introduction
Acute inflammation is a fundamental immune response that
occurs as a reaction to microbial infection or tissue injury, and
involves a complex sequence of events on both cellular and
molecular levels. It can be roughly divided into two phases,
the initial pro-inflammatory and the latter pro-resolving phase.
The pro-inflammatory phase of the response is initiated by
cells already present in the tissue, particularly resident macro-
phages and mast cells [1, 2]. Pro-inflammatory mediators,
such as eicosanoids and cytokines, are released upon activa-
tion of these cells, driving the recruitment and activation of
granulocytes [3, 4]. The extent of inflammation, the specific
type of leukocytes, and the produced mediators are tissue spe-
cific as well as dependent on the nature of the inflammatory
Electronic supplementary material The online version of this article
(doi:10.1007/s10719-015-9648-9) contains supplementary material,
which is available to authorized users.
* Yoann Rombouts
yoann.rombouts@ipbs.fr
1 Center for Proteomics andMetabolomics, Leiden UniversityMedical
Center, Leiden, The Netherlands
2 Department of Rheumatology, Leiden University Medical Center,
Leiden, The Netherlands
3 Institut de Pharmacologie et de Biologie Structurale, Université de
Toulouse, CNRS, UPS, Toulouse, France
4 Faculty of Medicine, Biomedical Center, School of Health Sciences,
University of Iceland, Reykjavik, Iceland
5 Department of Immunology and Center for Rheumatology Research,
Landspitali-The National University Hospital of Iceland,
Reykjavik, Iceland
6 Division of BioAnalytical Chemistry, VU University Amsterdam,
Amsterdam, The Netherlands
Glycoconj J (2016) 33:457–470
DOI 10.1007/s10719-015-9648-9
stimulus [5, 6]. For the initial pro-inflammatory phase cyto-
kines (e.g. IL-1, IL-6), acute phase proteins (APP) (e.g. C-
reactive protein) and eicosanoids (e.g. prostaglandins, leuko-
trienes) have been proven relevant [4, 7, 8]. As for the pro-
inflammatory phase, specific cells, proteins and molecules
have been described for the pro-resolution phase. These in-
clude resolution-promoting macrophages, proteins of the
lipoxygenase family, anti-inflammatory cytokines such as
IL-4 and IL-10, as well as lipid mediators like lipoxins and
E- and D-series resolvins [9]. Both the inflammatory and res-
olution phases are tightly controlled/connected and ideally
lead to tissue homeostasis. However, uncontrolled inflamma-
tory responses can cause local damage/scarring possibly lead-
ing to chronic injury [10, 11]. Such uncontrolled, non-
resolving inflammation is associated with many diseases, in-
cluding cancer, cardiovascular and the classic inflammatory
diseases, such as rheumatoid arthritis and inflammatory bowel
disease [12]. The resolution of acute inflammation and the
return to homeostasis are thus essential.
In addition to the aforementioned mechanisms, glycosyla-
tion of proteins influences many immunological processes.
This can be, among other means, by regulating half-life and
modulating the interaction of glycoproteins with carbohydrate
recognizing receptors (e.g. selectins) as well as by inducing
conformation changes of immunomodulatory proteins
[13–15]. As such, it is no surprise that inflammation has
shown to be closely associated with changes in glycosylation
(galactosylation, fucosylation, sialylation and bisection) of
major plasma proteins including immunoglobulin G (IgG)
and APP (e.g. alpha-1 antitrypsin) [13, 16, 17]. The abun-
dance of these proteins leads to changes in glycosylation being
detectable in the total plasma N-glycome (TPNG) [18, 19],
even though these changes are in part obscured by other pro-
tein glycosylation. For example, significant changes in both
IgG glycosylation and TPNGwere observed in patients only a
day after cardiac surgery [18]. This makes the analysis of
complex biofluids an interesting direction for fundamental
research and biomarker discovery, particularly with respect
to inflammatory processes. We have recently developed a ro-
bust analytical method allowing the high-throughput profiling
of the human plasma N-glycome by MALDI-TOF-MS [20,
21]. This approach relies on the linkage-specific chemical
derivatization of sialic acids enabling the discrimination of
α2-6-linked and α2-3/α2-8-linked sialic acids. Of note, far
from being restricted to the analysis of human plasma
N-glycome, this method is also suitable for glycome profiling
of other fluids and glycoprotein samples and for instance was
recently applied for studying glycosylation changes on IgG
during pregnancy [22].
The most frequently used model for investigating self-
resolving acute inflammation is the zymosan-induced perito-
nitis (ZIP) model, in which an insoluble polysaccharide pre-
pared from the cell wall of Saccharomyces cerevisiae is
injected into the peritoneum of mice [23–25]. Several investi-
gators have studied leukocyte recruitment, pro- and anti-
inflammatory lipid mediators, chemokines, cytokines as well
as metabolic profiles during inflammation using this model
[25–27]. However, to our knowledge no study has yet ad-
dressed a comprehensive analysis of glycomic changes during
the acute self-resolving inflammation induced by zymosan.
In the present study, we used the high-throughput MS-
based method described above for the comprehensive profil-
ing of the N-glycosylation in plasma and peritoneal fluid of
mice during the course of acute inflammation induced by zy-
mosan challenge.
Materials and methods
Zymosan-induced peritonitis and immunological profiles
Female C57BL/6 mice weighing 18–20 g (Taconic Europe,
Ejby, Denmark) were injected intraperitoneally (i.p.) with
0.5 mL of 2 mg/mL zymosan A (Sigma Aldrich, Steinheim,
Germany) solubilized in low-endotoxin sterile PBS (1 mg/
mouse) or with vehicle (control). At time points 0, 2, 4, 12,
24, 48, and 72 h after the injection of zymosan the mice were
anesthetized with isoflurane and the peritoneal cavity lavaged
with 5 mL ice-cold PBS without calcium and magnesium.
Following cervical dislocation blood was collected into EDTA
tubes. The blood was spun at 2000×g for 10 min, the plasma
aliquoted and stored under nitrogen at −80 °C until analysis.
The peritoneal lavage was spun at 225×g for 10 min, the fluid
was collected, aliquoted and stored under nitrogen at −80 °C
until analysis. The protein concentration was determined
using the Bradford method for both plasma and peritoneal
fluid. The peritoneal cells were resuspended in 1 mL PBS
and counted using a Countess automated cell counter. An
aliquot was kept for FACS analysis and the remaining cells
stored under nitrogen at −80 °C until analysis. The study was
approved by the Experimental Animal Committee, Ministry
for the Environment in Iceland. The zymosan-induced perito-
nitis model was carried out twice (n = 6) and the control
experiment once (n = 3).
FACS analysis
For phenotypic characterization, 3 × 105 peritoneal cells were
stained with fluorochrome-labeled monoclonal antibodies
against Ly6G, CD11b (BD Bioscience, San Jose, CA),
CXCR2 and F4/80 (BioLegend, San Diego, CA). Ten thou-
sand cells were collected using a Navios flow cytometer
(Beckman Coulter, Bromma, Sweden) and the Kaluza pro-
gram (Beckman Coulter) was used for analysis. Neutrophils
were identified as CXCR2+Ly6G+ cells and macrophages as
F4/80+CD11b+ cells.
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Measurement of interleukin-6 and leukotriene B4
concentrations in the peritoneal fluid of mice
Peritoneal fluid interleukin 6 (IL-6) concentration was deter-
mined using ELISA technology according to the manufac-
turer’s instructions (Mouse IL-6 ELISA Kit, BD Biosciences,
Breda, The Netherlands, # 555,240). Leukotriene B4 (LTB4)
was analyzed by solid phase extraction followed by LC-MS/
MS analysis according to published protocols [28, 29]. One
mL peritoneal lavage was worked up, avoiding the n-hexane
wash step, dissolving the sample in 200 μL 40 % MeOH for
LC-MS/MS analysis. Both IL-6 and LTB4 concentrations
were determined for one of the two zymosan-induced perito-
nitis experiments.
N-Glycan release from mouse plasma and peritoneal fluid
N-Glycans were released from the protein fraction as previ-
ously described [30]. To this end, 5 μL of plasma were dena-
tured with 10 μL 2 % sodium dodecyl sulfate (SDS; Merck,
Darmstadt, Germany) and incubated for 10 min at 60 °C. The
subsequent release step was performed by adding 10 μL of a
mixture containing 2 % Nonidet P-40 substitute (NP-40; Sig-
ma-Aldrich) and 0.5 mU recombinant peptide-N-glycosidase
F (PNGase F; Roche Diagnostics, Mannheim, Germany) in
2.5× PBS, followed by overnight incubation at 37 °C. In case
of peritoneal fluid, 100 μL of sample were dried by vacuum
centrifugation and solubilized in 10 μL Milli-Q (MQ) water
followed by 10 min sonication. The denaturing step was per-
formed by adding 20 μL 2% SDS for 10 min at 60 °C. The N-
glycans were released by adding 20 μL of a mixture contain-
ing 2 %NP-40 and 1 mU PNGase F in 2.5× PBS, followed by
overnight incubation at 37 °C.
N-Glycan derivatization and purification
The r e l e a s e d N - g l y c a n s we r e d e r i v a t i z e d by
ethyl esterification as described [20]. This derivatization
method allows a selective ethyl esterification of α2-6-linked
sialic acids and lactonization of α2-3-linked sialic acids. The
derivatization reagent was prepared by mixing 1-ethyl-3-(3-
dimethylaminopropyl) carbodiimide (EDC; Fluorochem,
Hadfield, UK) with 1-hydroxybenzotriazole (HOBt; Sigma-
Aldrich), resulting in a final concentration of 0.25 M in etha-
nol (Merck) for both reagents. For each sample, 2 μL of re-
leased N-glycans were added to 20 μL of derivatization re-
agent in a 96-well plate. The plate was sealed to prevent evap-
oration and incubated for 1 h at 37 °C. Following cool down to
room temperature, the derivatized glycans were purified by
hydrophilic interaction chromatography (HILIC) using pipette
tips filled with cotton as stationary phase [31]. Briefly, 20 μL
of ace ton i t r i l e (ACN; Bioso lve , Valkenswaard ,
The Netherlands) were added to the reaction mixture. The tips
(cotton inserted) were washed three times with 20 μL of MQ
water and three times with 20 μL of 85 % ACN followed by
sample loading by pipetting twenty times up and down. Final-
ly, cotton tips were washed by pipetting three times with
20 μL 85 % ACN containing 1 % trifluoroacetic acid (TFA;
Merck) and three times with 20 μL 85 % ACN, followed by
elution of samples in 10 μL MQ.
Matrix-assisted laser desorption/ionization time-of-flight
mass spectrometry (MALDI-TOF-MS) profiling of total
plasma N-glycome and total peritoneal fluid N-glycome
Each sample was measured once by mixing 5 μL of purified
derivatized glycans with 0.5 μL of 5 mg/mL 2,5-
dihydroxybenzoic acid (Bruker Daltonics, Bremen, Germany)
1 mM NaOH in 50 % ACN on a MTPAnchorChip 800/384
TF MALDI target (Bruker Daltonics) and left to dry at room
temperature. Subsequently, the dried sample spots were re-
crystallized by adding 0.2 μL ethanol. All analyses were per-
formed on an UltraFlextreme MALDI-TOF/TOF-MS
equipped with a Smartbeam II laser, controlled by proprietary
software Flexcontrol 3.4 (Bruker Daltonics). The Ultraflex
was operated in reflectron positive (RP) ion mode, calibrated
with a peptide calibration standard (Bruker Daltonics). For
sample measurements 10,000 laser shots were accumulated
at a laser frequency of 1000 Hz, using a complete sample
random walk with 200 shots per raster spot. Tandem mass
spectrometry (MALDI-TOF-MS/MS) was performed on the
most abundant peaks of the mouse N-glycome via laser-
induced dissociation. Fragmentation spectra were annotated
using GlycoWorkbench (version 2.1) [32].
Nano-liquid chromatography–mass spectrometry
(Nano-LC-MS) analysis of IgG Fc-glycosylation
IgG was isolated from 2 μL mouse plasma and 150 μL peri-
toneal fluid using protein G-Sepharose affinity chromatogra-
phy (GE Healthcare, Uppsala, Sweden), enzymatically
digested with trypsin and finally analyzed byMS as described
previously [33, 34]. Briefly, the tryptic IgG Fc N-glycopep-
tides were separated and analyzed on an Ultimate 3000 RSLC
nanoLC system (Thermo Scientific; Sunnyvale, CA, USA).
Separation was achieved on an Ascentis Express C18 nano-
LC column (Supelco; Bellefonte, USA) conditioned with
900 nL/min 0.1 % TFA in water (mobile phase A) after which
the following gradient of mobile phase A and 95 % ACN
(mobile phase B) was applied; 0 min 3 % B, 2 min 6 % B,
4.5 min 18 % B, 5 min 30 % B, 7 min 30 % B, 8 min 1 % B
and 11 min 1 % B. The MS detection was achieved using a
quadrupole-TOF-MS (maXis Impact HD ultra-high resolution
QTOF; Bruker Daltonics) [33, 34]. Sample ionization was
accomplished using a tapered spray tip (internal diameter
20 μm) and a CaptiveSpray ion source (both from Bruker
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Daltonics) with a spray voltage set at 1300 V. A CaptiveSpray
nanoBooster (Bruker Daltonics) was used with ACN saturated
nitrogen to enhance sensitivity (0.2 bar). Drying temperature
was set at 180 °C and drying gas-flow at 3 L/min (nitrogen
99.9990 %). Double and triple charged tryptic Fc glycopep-
tide signals were integrated and normalized to the subclass-
specific total sum as described elsewhere [34].
Data processing and statistical analysis
Automated MALDI-TOF-MS data processing was performed
by using an in-house developed software named MassyTools
[35]. MassyTools is released under the Apache 2.0 license and
is freely available on GitHub (https://github.com/Tarskin/
MassyTools). Briefly, spectra were exported as .txt file and
recalibrated using a defined list of calibrant masses. Only
spectra showing a signal-to-noise ratio (S/N) of 9 or above
(root-mean-square) for at least five calibration masses were
included for further analysis. The observed masses were then
assigned to N-glycan structures according to monosaccharide
composition, MALDI-TOF/TOF-MS/MS data, known bio-
synthetic pathways of glycans and literature [36–39]. Based
on this assignment, a glycan feature list including 94N-glycan
peaks was generated (Supplementary Table S2) and used to
proceed to the targeted data extraction of area-under-the-curve
of each N-glycan profile. During data extraction, MassyTools
dynamically determines the background around each isotopic
peak and subtracts it from the area of each analyte peak inten-
sity. Spectra exhibiting less than 45 % of the analyte area
above S/N values of 9 were excluded from further analysis.
Relative intensities of the defined set of 94 N-glycan peaks
were calculated for each spectrum by setting the sum of area-
under-the-curve values to 100 %. Furthermore, nineteen de-
rived traits were calculated based on the compositional fea-
tures (hexose = H; N-acetylhexosamine = N; fucose = F;
N-acetylneuraminic acid = E or L for α2-6- and α2-3-linked
variants respectively; N-glycolylneuraminic acid = Ge or Gl
for α2-6- and α2-3-linked variants respectively). The formu-
lae used to compute the derived glycosylation traits are de-
scribed in supplementary Table S1. Statistical analyses and
charts are based on biological replicates and were performed
by using GraphPad Prism 6.0 software. For the comparison of
glycosylation traits derived from total plasma N-glycome
(TPNG) and total peritoneal fluidN-glycome (TPFG) of mice,
paired t-test was used. A one-way analysis of variance
(ANOVA) with post-hoc Tukey test was used for the multiple
comparison of glycosylation traits in the different mice groups
at baseline (0 h) and 24 h. Statistical comparison of the derived
glycosylation traits between control and zymosan-induced
peritonitis mice at the different time points was performed
by two-way ANOVA with post-hoc Dunnett test. Data are
presented as mean ± standard error of the mean (SEM).
*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.
Results
Zymosan-induced peritonitis model and immunological
profiles
The zymosan-induced peritonitis model was used to investi-
gate the influence of acute inflammation on TPNG and TPFG.
To this end, female C57BL/6 mice were injected i.p. with
zymosan. The mice were sacrificed at 0 h (to provide a base-
line), 2, 4, 12, 24, 48 and 72 h and the plasma and peritoneal
fluid samples were collected. Two independent experiments
(1 and 2) were performed. As controls, a group of mice was
injected i.p. with PBS (vehicle). The injection of zymosan
resulted in a rapid, albeit transient elevation in the total num-
ber of peritoneal cells (Fig. 1a) [40]. The number of peritoneal
neutrophils peaked at 24 h following zymosan injection
(3.3 × 106 cells) and then gradually declined (Fig. 1b). In
contrast, a rapid decrease in the number of macrophages was
observed during the first 12 h, probably due to disappearance
of resident macrophages, followed by a rapid monocyte/
macrophage influx into the inflamed cavity, peaking at 48 h
after zymosan injection (1.8 × 106 cells) (Fig. 1c) [26, 40, 41].
The acute inflammatory response resulting from the zymosan
challenge was also reflected in a quick increase in the concen-
tration of IL-6 returning to control levels after 12 h (Fig. 1d).
A similar trend was observed for the concentration of leuko-
triene B4 (LTB4), a well-known eicosanoid mediating neutro-
phil chemotaxis (Fig. 1e) [26]. Importantly, injection with
PBS (control mice) only had minimal effects on the number
of total peritoneal cells, neutrophils and macrophages.
Characterization of mouse total plasma N-glycome
and total peritoneal fluid N-glycome
Initially, we characterized and compared the TPNG and the
TPFG at baseline (0 h). Both glycomes were generated by
performing a high-throughput release of N-glycans followed
by chemical derivatization of sialic acids allowing stabiliza-
tion and discrimination of α2-3−/α2-8- and α2-6-linked res-
idues [20]. TPNG and TPFG samples were analyzed by
MALDI-TOF(/TOF)-MS and the resulting data were proc-
essed using a new, in-house developed software for automated
data processing of mass spectra of glycoconjugates [35]. In
both glycomes, 94 peaks were assigned to glycan species ac-
cording to their calculated compositions of monosaccharides
and substituents (e.g. acetylation) and 19 derived glycosyla-
tion traits were calculated (Supplementary Tables S2 and S3).
Importantly, the main glycan compositions and the key struc-
tural features thereof were confirmed by MALDI-TOF/TOF-
MS/MS measurements (Supplementary Fig. S1).
As illustrated in Fig. 2, the TPNG and TPFG exhibit highly
similar glycosylation patterns. With more than 90 % of rela-
tive abundance, complex-type N-glycans predominate over
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high-mannose and hybrid-type species (Fig. 3 and
Supplementary Table S3). Of note, a slightly higher abun-
dance of high-mannose was observed in the TPFG
(mean ± SEM 1.4 % ± 0.2 %) as compared to TPNG
(0.9 % ± 0.1 %, p = 0.049, n = 3, paired), which occur at the
expense of complex-type N -g lycans (Fig. 3 and
Supplementary Table S3). The latter are mainly diantennary
glycoforms (87.3 % ± 0.3 % and 85.6% ± 0.7 % in TPNG and
TPFG, respectively) followed by triantennary (9.1 % ± 0.4 %
and 8.8 % ± 0.9 %, respectively), monoantennary
(2.6 % ± 0.0 % and 3.8 % ± 0.3 %, respectively) and tetra-
antennary species (<0.5 %) (Supplementary Table S3). Both
glycomes exhibit a very high level of galactosylation per an-
tenna (>95 %). Approximately 30 % of the glycans are
fucosylated, mainly mono-fucosylated (Supplementary Table
S3), with a fucose linked to the core GlcNAc residue as dem-
onstrated by MS/MS experiment, showing the loss of the
reducing end N-acetylglucosamine with fucose (−367.1 Da)
from fucosylated precursor masses and the presence of a
H3N2F1 fragment at m/z 1079.5 [M + Na]+(Supplementary
Fig. S1). However, a very low level (<0.3 %) of di-fucosylated
sialylated glycoforms (H4N4F2Gl1 and H5N4F2E1) was also
detected, thus suggesting presence of antennary fucosylation
(Supplementary Table S3). Fucosylation was detected in
mono-, di-, and triantennary species but not in tetra-
antennary glycans (data not shown). In both TPNG and
TPFG, the total level of sialic acids (NeuAc and NeuGc) per
antenna across all glycan species was over 97 %, with NeuAc
and NeuGc accounting for less than 1 % and more than 96 %,
respectively (Fig. 3 and Supplementary Table S3). Due to the
linkage-specific derivatization of sialic acids, we could distin-
guish that around 79 % of the glycan antennae contain
ethyl esterified NeuGc (Ge) indicating an α2-6-linkage,
whereas lactonized NeuGc (Gl), indicating α2-3- or possibly
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α2-8-linkage, were present on only 18 % of glycan antennae
(Fig. 3 and Supplementary Table S3).
The main glycan peak (H5N4Ge2) at m/z 2333.82 [M +
Na]+, which accounts for 30% of the total glycans, consists of
a fully galactosylated diantennary complex-typeN-glycan car-
rying two ethyl esterified (α2,6-linked) NeuGc (Ge) (Fig. 2,
Supplementary Fig. S1 and Table S2). This glycan can be
further extended by a core fucose (at m/z 2479.88) as well as
one O-acetyl group (OAc = 42.01 Da; m/z 2375.84), or two
OAc groups (+84.02 Da, m/z 2417.85). O-Acetylation is one
of the most frequent modifications of sialic acids, in which an
acetyl group is added to the hydroxyl group at C4, C7, C8,
and/or C9 of the sialic acid by sialate O-acetyltransferases
[42]. Accordingly, we only observed acetylation on sialylated
glycans, indicating that acetyl modifications are probably lo-
cated on NeuAc/NeuGc. This was also confirmed by the
mono-O-acetylated sialylated antennae fragments at m/z
400.6 (Ge1Ac1) and 765.5 (H1N1Ge1Ac1) observed in the
MALDI-TOF/TOF-MS/MS spectra of mono- and di-O-acet-
ylated glycans H5N4Ge2Ac1, H5N4F1Ge2Ac1 and
H5N4Ge2Ac2 (precursors at m/z 2375.84, 2521.89, 2417.85
[M + Na]+ respectively) (Fig. 4a and supplementary Fig. S1).
Furthermore, the fragment atm/z 808.1 (H1N1Ge1Ac2), pres-
ent in the MS/MS spectra of the di-acetylated glycan
H5N4Ge2Ac2, indicated that both OAc groups could be at-
tached to a single NeuGc rather than oneOAc on each NeuGc
(Fig. 4a). More generally, glycans from the peritoneal fluid
exhibit a significantly higher level of sialic acid acetylation
compared to plasma glycans (10.7 % ± 0.2 % vs
7.8 % ± 0.6 %, p = 0.016, n = 3, paired) (Fig. 3 and
Supplementary Table S3).
Another predominant glycoform (H5N4Ge1Gl1) at m/z
2287.78 [M + Na]+ is a fully galactosylated diantennary
complex-type N-glycan carrying one ethyl esterified (α2-6-
linked) N-glycolylneuraminic acid (Ge) and one lactonized
(α2-3-linked) N-glycolylneuraminic acid (Gl) (Fig. 2,
Supplementary Fig. S1 and Supplementary Table S2). This
glycan can also be further extended in a non-exclusive manner
by an acetyl group (e.g. H5N4Ge1Gl1Ac1 at m/z 2329.79), a
fucose (H5N4F1Ge1Gl1 atm/z 2433.84 [M+Na]+), or by one
or two (sialylated)-Gal-GlcNAc antennae giving rise to tri-
and tetraantennary glycans (e.g. H6N5Ge1Gl2 and
H7N6Ge1Gl2 atm/z 2941.99 and 3307.13 [M + Na]+, respec-
tively) (Supplementary Table S2). Importantly, an additional
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NeuGc residue can be further attached to H5N4Ge1Gl1 lead-
ing to trisialylated diantennary complex-type N-glycans as
described previously [36–39, 43]. The main trisialylated
diantennary species at m/z 2622.90 [M + Na]+ carries a
α2-6-linked N-glycolylneuraminic acid on one antenna and
bothα2-3-linked andα2,6-linkedN-glycolylneuraminic acids
on the galactose and the GlcNAc residues respectively of the
other antenna (Fig. 2 and Supplementary Table S2). This
structure was established by MALDI-TOF/TOF-MS/MS
analysis, which produced fragments at m/z 560.5 (N1Ge1),
at m/z 542.0 and m/z 1011.4 (H1N1Ge1Gl1) corresponding
to the D ion NeuGc-(α2-6)-HexNAc and the ion
NeuGc-(α2-3)-Hex-[NeuGc-(α2-6)-]HexNAc respectively
(Fig. 4b) [36, 44]. Moreover, the absence of fragments at m/z
630 (Ge1Gl1) excludes the possibility of a NeuGc-(α2-8)-
NeuGc motif (Fig. 4b). Of note, a higher level of sialylation of
the GlcNAc residue, named branching sialylation, was observed
in TPFG compared to TPNG (8.0 % ± 0.1 % vs 6.1 % ± 0.3 %,
p= 0.028, n = 3, paired) (Fig. 3 and Supplementary Table S3). In
addition to these fully galactosylated and sialylated glycans,
other related (truncated) glycoforms were detected such as
H3N3Ge1, H4N3Ge1, H4N4Ge1 and H5N4Ge1 at m/z
1471.52, 1633.58, 1836.65 and 1998.70 [M + Na]+ (Fig. 2
and Supplementary Table S2).
To summarize, TPNG and TPFG exhibit highly related
patterns that are characterized by a high level of fully
galactosylated and sialylated complex-type N-glycans with
or without core fucose. Sialic acids are predominantly NeuGc
residues on which one or two OAc groups can be attached.
Moreover, we have identified α2-6-sialylation of the
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antennary GlcNAc of diantennary complex-type N-glycans
that give rise to a disialylated antenna NeuGc-(α2-3)-
Gal-[NeuGc-(α2-6)]-GlcNAc.
Zymosan-induced peritonitis leads to rapid changes
of fucosylation and sialylation in TPNG and TPFG
We next analyzed the changes in glycosylation occurring in
TPNG and TPFG in response to zymosan or PBS (control)
administration. To this end, we first compared the TPNG- and
TPFG-derived glycosylation traits of zymosan-induced peri-
tonitis mice 24 h after injection of the zymosan, the time point
representing the peak of the inflammation (highest number of
peritoneal leukocytes). Again, highly similar glycosylation
patterns were observed between TPNG and TPFG (data not
shown). We next compared the derived glycosylation traits of
zymosan-induced peritonitis and control mice between 0 h
(baseline) and 24 h post-injection. As shown in Fig. 5 and
Supplementary Table S4, zymosan challenge induced several
significant modifications of glycosylation in both TPNG and
TPFG. Among the observed variations, the injection of
zymosan resulted in a significant increase of triantennary
complex-type N-glycans, which was not detected in control
mice (Supplementary Table S4). Likewise, mice challenged
with zymosan, but not controls, exhibit a significant decrease
in the percentage of TPNG fucosylation after 24 h (Fig. 5a). A
similar decrease of fucosylation level, albeit not statistically
significant, was also observed in TPFG (Fig. 5b). In addition,
zymosan-induced peritonitis led to a significant rise of the
sialylation level in TPNG and TPFG, which is mainly due to
a rise in the proportion of both α2-3-linked NeuGc and
branching sialylation (Fig. 5). Likewise, although very low
in abundance, both α2,3-linked and α2-6-linked NeuAc in-
creased in TPNG and TPFG of mice 24 h after injection of the
zymosan but not in control mice glycomes. In contrast, there
was no clear evidence of changes in α2-6-linked N-
glycolylneuraminic acid (Supplementary Table. S4). Finally,
the acute zymosan-induced inflammation induced a signifi-
cant decrease in the abundance of acetylated glycans
(Supplementary Table S4). At the glycan level, the decrease
of H5N4F1Ge2 and H5N4F1Ge2Ac1 as well as the increase
of H4N4Ge2Gl1 were clearly identified as the main drivers of
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the changes in fucosylation, acetylation and sialylation (data
not shown).
In order to define the time point at which significant chang-
es in glycosylation of zymosan-treated mice occur, we longi-
tudinally analyzed selected glycosylation features including
fucosylation, sialylation, α2-3-linked NeuGc and branching
sialylation (Fig. 6, Supplementary Figure S2 and Table S5).
We observed that the fucosylation level reached a minimum
value at 24 h after zymosan challenge and then remained
constant until at least the 72 h time point. In contrast, the
sialylation-derived traits peaked at 48 h and then gradually
declined. More importantly, as compared to control mice, sig-
nificant changes in glycosylation of both TPNG and TPFG
were observed in mice already at the 12 h time point, hence
demonstrating unexpected velocity of the biological mecha-
nisms involved. Of note, these results were successfully
reproduced in a second independent zymosan-induced perito-
nitis experiment (Exp 2) (Fig. 6, Supplementary Figure S2 and
Table S5).
No changes in the glycosylation of plasma and peritoneal
fluid IgG were observed following zymosan-induced
peritonitis in mice
It has now been clearly established that the Fc-linked glyco-
sylation pattern of IgG, i.e. the level of sialylation,
galactosylation and fucosylation, regulate the pro- or anti-
inflammatory activity of antibodies through the modulation
of binding to Fcγ-receptors, lectins (e.g. DC-SIGN) and pro-
teins of the complement system [45–47]. Accordingly, chang-
es in IgG glycosylation are associated with some physiologi-
cal (e.g. pregnancy) and pathological conditions (e.g. rheuma-
toid arthritis) [17, 48, 49]. Recently, alterations of the IgG
glycosylation pattern have been observed in patients within
24 h after heart surgery [18]. Therefore, we sought to deter-
mine whether acute inflammation in mice, due to zymosan-
induced peritonitis, could also lead to a rapid reshaping of IgG
glycosylation. To this end, the N-glycosylation of IgG was
analyzed in a subclass-specific manner (IgG1, IgG2, IgG3)
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Fig. 5 Comparison of selected
derived glycosylation traits in the
a TPNG and b TPFG of mice at
time point 0 h and 24 h following
challenge with zymosan (ZIP) or
PBS (control). Description of the
glycosylation features is provided
in Fig. 3. Data belong to the first
experiment of zymosan-induced
peritonitis. Statistical analysis was
performed for all glycosylation
traits using a one-way analysis of
variance (ANOVA) with post-hoc
Tukey test (n = 3) (Supplementary
Table S4). *p < 0.05; **p < 0.01;
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using a previously established LC-ESI-MS(/MS) method [16,
33, 34]. As observed for the glycomes, similar if not identical
glycosylation features were found in IgG isolated from plasma
and peritoneal fluid of mice (Supplementary Table S6). How-
ever, in contrast to TPNG and TPFG glycosylation, no signif-
icant differences in antibody galactosylation, sialylation and
fucosylation could be detected between zymosan-induced
peritonitis and controls, or across time points, for any of the
IgG subclasses (Fig. 7, Supplementary Fig. S3 and Table S6).
Discussion
Most of the in vivo immunological and medical research relies
on mouse models, which are essential for elucidating mecha-
nisms of (human) disease, as well as for translational research
from bench to bedside. The murine zymosan-induced perito-
nitis is a widely used model to decipher the cellular and mo-
lecular mechanisms associated with acute inflammation and
its controlled resolution. Among the large number of changes
accompanying inflammation, significant variations in concen-
trations of many plasma and peritoneal proteins, known as
acute-phase proteins (APP), have been observed [6]. As
APP are glycosylated, many inflammatory conditions also
result in alterations in total plasma protein glycosylation
[13]. In this context, our study aimed at analyzing the dynamic
changes in N-linked glycosylation of plasma and peritoneal
fluid proteins occurring in mice during the course of self-
resolving zymosan-induced acute inflammation.
The TPNG and TPFG were prepared and analyzed using a
fast and reliable MALDI-TOF-MS–based analytical method
as previously described [20, 21]. Among other advantages,
this method enables the stabilization and selective derivatiza-
tion of α2-6-linked and α2-3-linked sialic acids as well as the
identification of glycan substituents such as OAc groups.
Structural analysis revealed a high similarity between TPNG
and TPFG, which is in agreement with the important fluid
exchange occurring between plasma and the peritoneal cavity
[36]. In both glycomes, highly galactosylated and sialylated
di- and triantennary complex type N-glycans predominated
[36, 38]. In contrast to the NeuAc found in human, sialic acid
residues in mouse TPNG and TPFG are almost exclusively
NeuGc. Likewise, the high degree of sialylation observed in
mice is in part due to the presence of disialylated antennae
NeuGcα2-3-Galβ1-3-[NeuGcα2-6-]GlcNAc that, to our
knowledge, has not been reported in humans. Of note, exis-
tence of such Bbranching sialylation^ in mouse serum and
liver tissue has been previously, rigorously characterized by
NMR and MS/MS [36–39, 43]. Serotransferrin, haptoglobin,
prothrombin and fibronectin have been identified as protein
carriers for this disialylated epitope [36, 39, 50]. In addition to
branching sialylation, we found that mouse N-glycomes con-
tain O-acetylated sialic acids [38]. Although the meaning of
this modification is far from clear, it has been shown that
O-acetylation can block the recognition of sialic acids by in-
trinsic lectins (e.g. Siglecs) and modulate positively or nega-
tively the interaction with microbial lectins [42]. Finally,
fucosylation was detected in less than one-third of the glycans
and MS/MS analyses demonstrated that fucose residues are
mainly attached to the core GlcNAc of glycans. In other
words, we were unable to demonstrate the presence of anten-
nae fucose and Lewis-type antigens in mouse plasma and
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Fig. 6 Longitudinal analysis of
fucosylation, sialylation, α2-3-
linked NeuGc and branched
sialylation levels of the total
peritoneal fluid N-glycome of
mice following challenge with
zymosan or PBS (control). Data
belong to two independent
zymosan-induced peritonitis
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analysis of variance (ANOVA)
followed by a Dunnett test (n = 2–
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peritoneal fluid N-glycans, which is in agreement with the
literature [36, 38, 51]. Of note, the sialyl LewisX epitope is
present in human plasma N-glycans, carried by acute phase
proteins and has often been associated with inflammation and
disease severity [18, 20, 52–56].
We demonstrated that both mouse TPNG and TPFG are
altered rapidly in response to zymosan-induced peritonitis.
Especially, within 12 h, we observed a significant increase in
the sialylation level together with a significant decrease of
core fucosylation. Similar alterations in glycosylation have
been previously reported in rat and mouse plasma proteins
following turpentine oil-induced inflammation as well as in
human total serum protein during the early course of sepsis
and acute pancreatitis [55, 57–60].
We further showed that the rise in the level of mouse N-
glycome sialylation after zymosan injection results from in-
creases in α2-3-linked NeuGc and branching sialylation. Al-
though this finding is novel, increase of branching sialylation
of serum N-glycans has been previously observed in mice
with colon cancer or during murine ovarian tumor progression
stimulated by injections of pro-inflammatory drugs
(thioglycolate or chlorite-oxidized oxyamylose) [36, 37].
The mouse sialyltransferase responsible for the addition of
NeuGcα2-6 on the GlcNAc of the NeuGcα2-3-Galβ1-3-
GlcNAc antenna has not been identified yet. However, en-
zymes with such activity have been previously characterized
in the rat, fetal calf, rabbit and human liver, and placenta [61,
62]. These enzymes showed optimal activity with NeuGcα2-3-
Galβ1-3-GlcNAc- acceptor structure but very low activity with
the Galβ1,3-GlcNAc- sequence. If a similar enzyme exists in
mouse liver, one can propose that the increase of branching
sialylation is a direct consequence of the increase ofα2-3-linked
NeuGc. Notably, one possible enzyme candidate in mice is
ST6Ga lNAc VI tha t exh ib i t s a c t i v i t y towa rds
sialyllactotetraosylceramide (NeuAcα2-3-Galβ1-3-
GlcNAcβ1-3-Galβ1-4-Glcβ1-Cer) and whose mRNA tran-
script increases in the liver with inflammation [59, 63].
Several non-exclusive hypotheses can be proposed to ex-
plain the unexpectedly rapid changes in mouse glycomes fol-
lowing zymosan-induced peritonitis. First, the observed alter-
ations in N-glycosylation could result from a rapid synthesis
of cytokines/chemokines (e.g. IL-6) that induce quantitative
changes of APP produced by the liver. This would imply a
rapid synthesis of cytokines and APP with visible effects in
the plasma and peritoneal fluid glycosylation. In line with this
hypothesis, we showed that IL-6 peaked at 12 h post-injection,
whereas the maximal glycosylation changes were observed
between 24 and 48 h. Also, important changes in concentra-
tions of glycosylated APP (e.g. haptoglobin, hemopexin, se-
rum amyloid A) can already be detected in mice between 24 h
and 48 h after induction of inflammation by i.p. injection of
LPS [64–66]. In a second scenario, inflammatory mediators
could directly affect the glycan composition of plasma pro-
teins by regulating the biosynthetic pathways of glycosylation
in the plasma protein producing cells. Accordingly, the rapid
changes in rat plasma glycosylation in response to turpentine-
oil inflammation occurred not only in positive APP (i.e. α1-
acid glycoprotein, α2-macroglobulin), whose serum concen-
trations increase during inflammation, but also in negative
APP (α1-inhibitor 3) and in non-acute phase proteins (α1-
macroglobulin) produced by the liver [60]. Also, in vitro stim-
ulation of hepatocytes and hepatoma cell lines with
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inflammatory stimuli (e.g. IL-6, TGF-β, TNF-α) leads to a
direct modification of APP N-glycosylation [67]. Under the
third hypothesis, changes in mouse N-glycosylation induced
by zymosan challenge could be the consequence of a
reshaping of plasma and peritoneal fluid protein glycosylation
by circulating or membrane-bound glycosyltransferases and
glycosidases, or following reversible endocytosis of plasma
proteins by cells [60, 68]. The detection of a number of gly-
cosyltransferase activities in systemic circulation supports this
hypothesis [69]. The activity of blood glycosyltransferases,
especially sialyltransferases, is increased during acute/
chronic inflammation in mouse models and impacts the
sialylation of IgG [70–72]. These extracellular enzymes may
also be responsible for the extensive changes in human IgG
glycome composition in the 24 h period following cardiac-
surgery, which is unlikely to be the result of the production
of new IgGs [18]. However, in this study, no significant
change in mouse IgG glycosylation has been observed during
zymosan-induced inflammation.
In summary, we demonstrated that rapid changes in mouse
plasma and peritoneal fluid N-glycosylation occur during
zymosan-induced peritonitis. Fucosylation, α2-3-linked
NeuGc and branching sialylation represent markers of acute
inflammation in mice. Future research should now focus on
how these changes in glycosylation are caused, and how they
may modulate the function of plasma and peritoneal acute
phase proteins [13].
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